Chickenpox
Also known as: Varicella
Methodology & AI Transparency ⓘ
Chickenpox Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Chickenpox is an infection caused by the varicella-zoster virus.
- 2 Real-world patient consensus: Diagnostic registry B01.9: Chickenpox is managed within Infections & Antivirals (aka Varicella).
- 3 Typical cash cost range: Primary evaluation for Chickenpox incorporates bacterial/fungal culture with in Chickenpox (B01.9: antimicrobial susceptibility testing) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Chickenpox: maintaining C-Reactive Protein / in Chickenpox (B01.9: Procalcitonin) within Resolution to baseline (B01.9).
Ask our AI Specialists anything about Chickenpox
What Is Chickenpox?
Chickenpox is an infection caused by the varicella-zoster virus. Most cases are in children under age 15, but older children and adults can get it. It spreads very easily from one person to another. The classic symptom of chickenpox is an uncomfortable, itchy rash. The rash turns into fluid-filled blisters and eventually into scabs. It usually shows up on the face, chest, and back and then spreads to the rest of the body. Other symptoms include: Fever Headache Tiredness Loss of appetite Chickenpox is usually mild and lasts 5 to 10 days. Calamine lotions and oatmeal baths can help with itching. Acetaminophen can treat the fever.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Chickenpox (code B01.9) is or latent viral in Chickenpox (B01.9: reactivation within sensory), Cross-referenced with NIH MeSH (Chickenpox), which Bacterial, Viral & Fungal Infections clinicians address while surveilling C-Reactive Protein / in Chickenpox (B01.9: Procalcitonin) (Resolution to baseline (B01.9)).
Common Symptoms & Clinical Signs
- • Presentation of Chickenpox (B01.9): sore throat, productive in Chickenpox (B01.9: cough, sinus/ear pain,)
- • Secondary Chickenpox clinical sign: painful vesicular rash in Chickenpox (B01.9: in a dermatomal)
- • Symptom flares in Chickenpox correlating with C-Reactive Protein / in Chickenpox (B01.9: Procalcitonin) deviation outside Resolution to baseline (B01.9)
- • Functional infections & antivirals impact requiring bacterial/fungal culture with in Chickenpox (B01.9: antimicrobial susceptibility testing) evaluation (B01.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Chickenpox Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B01.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: C-Reactive Protein / in Chickenpox (B01.9: Procalcitonin) | Resolution to baseline (B01.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Chickenpox (B01.9: Culture & Sensitivity) | Pathogen clearance / negative test (B01.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Chickenpox (B01.9: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B01.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Chickenpox
Treatment selection for Chickenpox depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Chickenpox)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Correlation of protection against varicella in a randomized Phase III: What a 5,803-Participant Study Found Varicella-specific antibody concentrations are a good predictor of protection, given their inverse correlation with varicella occurrence. Vaccine • 2021-06-08 • Phase III Randomized Trial | N = 5,803 | 90/100 | PMID 33736915 ↗ |
| Can This Approach Help? Inside the Latest Research on Immunogenicity and safety profiles of a new MAV/06 strain varicella vaccine in Furthermore, the MG1111 and control vaccine groups were not significantly different in the percentage of participants showing side effects-solicited, local, or systemic during 43-day period of observation and serious side... Vaccine • 2021-03-19 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33627245 ↗ |
| Can This Approach Help? Inside the Latest Research on Immunogenicity and safety of a live attenuated varicella vaccine in children aged The freeze-dried live attenuated VarV developed by Beijing Minhai Biotechnology Co. Human vaccines & immunotherapeutics • 2025-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39895085 ↗ |
| Can This Approach Help? Inside the Latest Research on Influenza vaccines promote humoral and cellular immune responses: a randomized, Both QIVs elicit significant increases in antibody titers 28 days after vaccination; Sinovac-QIV induces 9-10-fold increases in geometric mean titers, while Vaxigrip-Tetra™ elicits 7-8-fold increases (p + and CD8 + T cell... Nature communications • 2025-12-07 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41354738 ↗ |
| Can This Approach Help? Inside the Latest Research on Immunogenicity and safety of a live attenuated varicella vaccine in healthy The test freeze-dried live attenuated VarV demonstrated good immunogenicity and higher safety compared to the active control vaccine in healthy participants aged 13-55 years. Expert review of vaccines • 2025-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39916494 ↗ |
Chickenpox Patient Community & “People Like Me” Threads
Filter Chickenpox community threads and patient logs by age, biological sex, dosage, and treatment duration.